glp 1 ibd Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential The alleviating effect and mechanism
Description
FDA updates rules on compounded GLP-1 drugs, impacting patients and providers
These effects were partially attenuated by GLP-1R small interfering RNA treatment
Main outcome measures Thyroid cancer identified from nationwide cancer registers
The weight loss market is undergoing a seismic shift as the focus moves from injectable peptides to oral small molecule GLP-1 receptor agonists, led by Eli Lillys promising candidate, orforglipron
This consensus paper aims to provide guidance on the utilization of DPP-4 inhibitors in T2DM management from an Indian perspective
